'Flt3 itd' presentation slideshows

Is there anything new for relapsed AML?

Is there anything new for relapsed AML?. Steven M. Kornblau, M.D. Department of Leukemia Department of Stem Cell Transplantation and Cellular Therapy. The Status Quo. Most patients achieve remission 80% < age 60, no AHD 50% >60 or prior AHD Most relapse

511 views • 44 slides

Is there anything new for relapsed AML?

Is there anything new for relapsed AML?. Steven M. Kornblau, M.D. Department of Leukemia Department of Stem Cell Transplantation and Cellular Therapy. The Status Quo. Most patients achieve remission 80% < age 60, no AHD 50% >60 or prior AHD Most relapse

445 views • 44 slides

933 views • 38 slides

FLT3 and NPM1 Testing in Acute Myeloid Leukaemia

FLT3 and NPM1 Testing in Acute Myeloid Leukaemia. Louise Stanley Northern Genetics Service April 2010. Acute Myeloid Leukaemia (AML). Uncontrolled proliferation of immature myeloid cells (blast) Median age of onset ~60 years

591 views • 25 slides

CLINICAL CASE 91

257 views • 25 slides

FLT3-ITD and NPM1 gene mutations

Improvement of leukemia free survival and reduction of relapse incidence by allogeneic stem cell transplantation in elderly patients with AML irrespective of the FLT3-ITD mutation and NPM1 status (except NPM1mut/FLT3wt).

449 views • 21 slides

334 views • 17 slides

"FLT3-ITD and FLT3 Inhibitors in the Setting of Allogeneic Stem Cell Transplantation for AML"

322 views • 14 slides

"FLT3-ITD and FLT3 Inhibitors in the Setting of Allogeneic Stem Cell Transplantation for AML"

315 views • 14 slides

"FLT3-ITD and FLT3 Inhibitors in the Setting of Allogeneic Stem Cell Transplantation for AML"

150 views • 14 slides